These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 32067585)
1. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial. Núñez J; Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Lupón J; Navarro J; Górriz JL; Sanchis J; Chorro FJ; Comín-Colet J; Bayés-Genís A; J Am Heart Assoc; 2020 Feb; 9(4):e014254. PubMed ID: 32067585 [TBL] [Abstract][Full Text] [Related]
2. Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design. Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Sanchis J; Chorro FJ; Bayés-Genís A; Núñez J; Clin Cardiol; 2018 Jun; 41(6):729-735. PubMed ID: 29607528 [TBL] [Abstract][Full Text] [Related]
3. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA; Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395 [TBL] [Abstract][Full Text] [Related]
4. Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial. Del Canto I; Santas E; Cardells I; Miñana G; Palau P; Llàcer P; Fácila L; López-Vilella R; Almenar L; Bodí V; López-Lereu MP; Monmeneu JV; Sanchis J; Moratal D; Maceira AM; de la Espriella R; Chorro FJ; Bayés-Genís A; Núñez J; J Am Heart Assoc; 2022 Apr; 11(7):e022214. PubMed ID: 35301854 [TBL] [Abstract][Full Text] [Related]
5. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A; Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470 [TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356 [TBL] [Abstract][Full Text] [Related]
7. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124 [TBL] [Abstract][Full Text] [Related]
8. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF; Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690 [TBL] [Abstract][Full Text] [Related]
9. Ferric carboxymaltose in patients with heart failure and iron deficiency. Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P; N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054 [TBL] [Abstract][Full Text] [Related]
10. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327 [TBL] [Abstract][Full Text] [Related]
11. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis. Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA; Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919 [TBL] [Abstract][Full Text] [Related]
12. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency. Charles-Edwards G; Amaral N; Sleigh A; Ayis S; Catibog N; McDonagh T; Monaghan M; Amin-Youssef G; Kemp GJ; Shah AM; Okonko DO Circulation; 2019 May; 139(21):2386-2398. PubMed ID: 30776909 [TBL] [Abstract][Full Text] [Related]
13. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). Yeo TJ; Yeo PSD; Hadi FA; Cushway T; Lee KY; Yin FF; Ching A; Li R; Loh SY; Lim SL; Wong RC; Tai BC; Richards AM; Lam CSP ESC Heart Fail; 2018 Apr; 5(2):344-353. PubMed ID: 29345426 [TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD; Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939 [TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856 [TBL] [Abstract][Full Text] [Related]
16. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing. Diebold M; Kistler AD BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916 [TBL] [Abstract][Full Text] [Related]
18. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD; BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881 [TBL] [Abstract][Full Text] [Related]
19. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Geisser P; Banké-Bochita J Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]